Literature DB >> 11027799

Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose.

P Landry1, S Tremblay, R Darioli, B Genton.   

Abstract

We investigated what happens with the immune response when people come back for their booster dose of inactivated hepatitis A vaccine later than the recommended time of 6-12 months after the primary dose. We recruited a group of 124 travellers who received either the primary doses of Havrix 720 (two doses) or of Havrix 1440 (one dose) >/=24 months before study entry. They received a booster dose of Havrix 1440 and blood was drawn 1 month later. As a control group, we recruited a group of 125 travellers who followed a recommended schedule with a primary dose at month 0 and a booster dose at months 6-12. For both study groups, the GMTs increased dramatically and similarly upon the booster immunisation. Although significantly more late travellers (32%) had lost detectable antibodies than controls (11%) before administration of the booster dose, all these subjects showed an anamnestic response to the booster dose. Delaying the booster dose up to 66 months after primary vaccination did not seem to influence the immunogenicity of the booster dose. However, the recommended 6-12-month interval remains if detectable antibody titers are to be warranted constantly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027799     DOI: 10.1016/s0264-410x(00)00188-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

2.  [Prevention of virus hepatitis A to E].

Authors:  M Cornberg; M P Manns
Journal:  Internist (Berl)       Date:  2011-03       Impact factor: 0.743

Review 3.  Paediatric travel medicine: vaccines and medications.

Authors:  Mike Starr
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

4.  Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years.

Authors:  Christoph Hatz; Robert van der Ploeg; Bernhard R Beck; Gert Frösner; Marjory Hunt; Christian Herzog
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

Review 5.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 6.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

7.  The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adults.

Authors:  Jiseun Lim; Yeong-Jun Song; Woong-Sub Park; Haesook Sohn; Moo-Sik Lee; Dong-Hoon Shin; Chun-Bae Kim; Hwasung Kim; Gyung-Jae Oh; Moran Ki
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

8.  Factors related to completed status and seropositivity of hepatitis a immunization among children aged 1-3 years and 6-8 years in South Korea.

Authors:  Jee-Young Hong; Mo Ran Ki; Hye-Jung Hwang; Delacroix Sinny; Young-Joon Park; Geun-Ryang Bae; Moo-Sik Lee
Journal:  Osong Public Health Res Perspect       Date:  2013-04

9.  Hepatitis A immunity in the District of Aveiro (Portugal): an eleven-year surveillance study (2002-2012).

Authors:  Sara Pereira; Inês Linhares; António Ferreira Neves; Adelaide Almeida
Journal:  Viruses       Date:  2014-03-14       Impact factor: 5.048

10.  Seropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus.

Authors:  Yeong-Jun Song; Jiseun Lim; Woong-Sub Park; Haesook Sohn; Moo-Sik Lee; Dong-Hoon Shin; Chun-Bae Kim; Hwasung Kim; Gyung-Jae Oh; Moran Ki
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.